Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale to start Eloisa pilot in public healthcare

HEALTHAnalyst Comment15.09.2026 klo 08.19
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health announced a pilot project in South Savo, integrating its disease risk detection test into public primary healthcare, marking the first phase of a cooperation initiated in June 2025.
  • The project offers free tests to residents aged 45, 50, and 55, identifying risks for five chronic diseases, with follow-up digital lifestyle coaching and testing funded by Sitra and Eloisa.
  • The pilot is seen as a strategic opportunity for Nightingale to establish a presence in the public healthcare sector, although its immediate financial impact is expected to be limited.
  • Long-term economic benefits are anticipated through extensive partnerships and increased volumes, with the pilot potentially leading to broader public sector contracts.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 09/15/2026 at 07:15 am EEST

Nightingale Health announced on Monday that residents of the South Savo Wellbeing Services County Eloisa, can register for the Wellbeing Gift (Hyvinvointilahja) research and development project. In the project, the company’s disease risk detection test is offered as part of primary healthcare. This is the first practical phase of the cooperation announced in June 2025. We view the news as a positive step forward, as it opens the door for the company into Finland's public primary healthcare. As this is a regional pilot project, we estimate that its immediate financial impact will remain limited for the time being. The news therefore does not cause immediate changes to our forecasts.

The pilot provides an important proving ground in the public sector

In the project, Eloisa offers its 45-, 50-, and 55-year-old residents Nightingale's test free of charge, which identifies the risk of developing five common chronic diseases. Individuals identified with an elevated risk are directed to digital lifestyle coaching, and a follow-up test conducted after six months shows how the disease risks have changed. The project is funded by Sitra and Eloisa, and scientific evaluation is led by the University of Eastern Finland. As we have previously estimated, the public healthcare sector opens up opportunities for Nightingale, but breaking into a slow-moving industry takes time. We believe that the project starting now is a good reference and a chance to prove itself for the company. This enables the company to demonstrate the impact of the operating model in public healthcare before a potential broader roll-out.

Economic scale is built over the long term

While the public sector breakthrough is strategically important, we estimate that the project's volumes and thus its direct revenue impact will remain moderate in the initial phase. The scaling of Nightingale's business model and the profitability turnaround necessitate that the company builds extensive partnerships with a long-term perspective and increases the volumes of existing agreements. We will follow the results of the Eloisa pilot with interest and its potential to act as a spearhead for broader public sector contracts in the future.

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures12.06.

202526e27e
Revenue4.75.910.2
growth-%7.7 %25.9 %71.7 %
EBIT (adj.)-19.4-17.8-13.9
EBIT-% (adj.)-413.7 %-301.2 %-137.3 %
EPS (adj.)-0.30-0.29-0.21
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Here are Antti’s comments on how to start the Eloisa pilot in the Etelä-Savo wellbeing services county by offering a disease risk identification...
4 hours ago
by Sijoittaja-alokas
6
Inderes – 11 Sep 26 Nightingale H2'26 -ennakko: Kasvua tutkimushankkeiden ja Terveystalon vetämänä... Ennustamme H2-liikevaihdon kasvaneen 47...
9/11/2026, 4:40 AM
by Pertti
4
[quote="Antti_Siltanen, post:2831, topic:14314"]\nkun kassaa on kuitenkin nykyisellä polttotahdilla yli kolmeksi vuodeksi\n[/quote]\n\nSurely...
9/10/2026, 5:37 AM
by Puutaheinää
1
Yeah, important topic, let’s try to think of an approach. A question like this easily ends up a bit vague and easy for the CEO to deflect, since...
9/10/2026, 5:30 AM
by Antti Siltanen
13
Inderes – 10 Sep 26 Nightingale laajentaa Kroatiaan - Inderes Kaupallista sopimusta edelsi kolme onnistunutta pilottia. “We consider it particularly...
9/10/2026, 5:13 AM
by Pertti
5
On Wednesday, the annual report might shed some light on the matter. Maybe.
9/10/2026, 12:01 AM
by Pertti
0
@Antti_Siltanen it would be nice in the CEO interview to have a little inquiry about the sufficiency of the cash position in relation to revenue...
9/9/2026, 8:02 PM
by Cle
0